A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targetin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjeldsen, Julie Westerlin, Lorentzen, Cathrine Lund, Martinenaite, Evelina, Ellebaek, Eva, Donia, Marco, Holmstroem, Rikke Boedker, Klausen, Tobias Wirenfeldt, Madsen, Cecilie Oelvang, Ahmed, Shamaila Munir, Weis-Banke, Stine Emilie, Holmström, Morten Orebo, Hendel, Helle Westergren, Ehrnrooth, Eva, Zocca, Mai-Britt, Pedersen, Ayako Wakatsuki, Andersen, Mads Hald, Svane, Inge Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904254/
https://www.ncbi.nlm.nih.gov/pubmed/34887574
http://dx.doi.org/10.1038/s41591-021-01544-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904254/
https://www.ncbi.nlm.nih.gov/pubmed/34887574
http://dx.doi.org/10.1038/s41591-021-01544-x

Ejemplares similares